Results 111 to 120 of about 58,715 (292)

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Current trends in the treatment of hepatic encephalopathy

, 2009
Mohamad Rasm Al Sibae, Brendan M McGuireDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USAAbstract: Hepatic encephalopathy (HE) is a common reversible neuropsychiatric syndrome ...
Mohamad Rasm Al Sibae, Brendan M McGuire
core  

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Zinc Deficiency in Patients of Chronic Hepatic Encephalopathy

Journal of Rawalpindi Medical College, 2018
Background : To determine the zinc deficiency in patients with chronic hepatic encephalopathy Methods: In this cross section study decompensated hepatic cirrhosis diagnosed patients (n=102) aged>16 years,both gender, with hepatic encephalopathy as per ...
Shabana Lakho et al.,
doaj  

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs

, 2015
Daniela Paola Roggeri,1 Alessandro Roggeri,1 Elisa Rossi,2 Elisa Cinconze,2 Antonio Gasbarrini,3 PierAlessandro Monici Preti,4 Marisa De Rosa,2 1ProCure Solutions, Nembro, Bergamo, 2CINECA, Interuniversity Consortium, Bologna, 3Catholic University of ...
Roggeri DP, Rossi E, Gasbarrini A, Roggeri A, Monici Preti P, De Rosa M, Cinconze E   +6 more
core  

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure

Artificial Organs, EarlyView.
Extracorporeal albumin dialysis (OPAL) effectively reduces bilirubin and improves other laboratory markers in posthepatectomy liver failure, particularly in secondary forms. It may serve as a bridging therapy to support hepatic recovery in critically ill patients, although prospective studies are needed to confirm its impact on survival.
Dorian Marckmann, Emely Wack, Luisa Schäfer, H. Christian Hillebrecht, Francesca Reimer, Gabriel Stöger, Klara Krötzsch, Magdalena Menzel, Lampros Kousoulas, Stefan Utzolino, Stefan Fichtner‐Feigl, Dawid L. Staudacher, Frederic Arnold, Thomas Welte, Philipp Holzner, Felix A. Rottmann, Christopher Berlin   +16 more
wiley   +1 more source

Hepatic encephalopathy: what the multidisciplinary team can do

, 2017
Andy Liu,1 Eric R Yoo,2 Osama Siddique,3 Ryan B Perumpail,4 George Cholankeril,5 Aijaz Ahmed4 1Department of Medicine, California Pacific Medical Center, San Francisco, CA, 2Department of Medicine, University of Illinois College of Medicine, Chicago, IL,
Perumpail RB, Cholankeril G, Liu A, Yoo ER, Ahmed A, Siddique O   +5 more
core  

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Alimentary Pharmacology &Therapeutics, EarlyView.
Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs   +14 more
wiley   +1 more source

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source